NCT00567762View on ClinicalTrials.gov

Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

September 30, 2004

Conditions
KeratoconjunctivitisConjunctivitis
Interventions
DRUG

FK506

Opthalmic suspension

DRUG

placebo

placebo eye drops

Trial Locations (8)

Unknown

Ehime

Hokkaido

Kagoshima

Kochi

Miyazaki

Osaka

Tochigi

Tokyo

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00567762 - Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis | Biotech Hunter | Biotech Hunter